The Hill may be compensated and/or receive an affiliate commission if you buy through our links.
Events of the past year or so have challenged our collective mental health in ways we never could have imagined before 2020. Unfortunately, not enough people prioritize this crucial aspect of daily life, but healthcare innovations continue to create new opportunities.
Fisher Wallace Laboratories is among those innovators. The realities of COVID and its far-ranging ramifications impact each of us in unique ways, leaving some left feeling alone and vulnerable. These developments have created a need for reevaluation of modern mental health care approaches, as traditional therapies have become increasingly costly and outdated.
Noninvasive relief for those who need it
Fisher Wallace is looking to set the pace down a more promising path, developing a new FDA-cleared product primed to drastically alter the way many of us explore self-betterment. Navigating a new course in non-surgical electronics for the brain, Fisher Wallace has unveiled its Stimulator device, which has been utilized by more than 70,000 patients and is currently undergoing review by the FDA for full approval.
Already provided clearance, the Fisher Wallace Stimulator has exhibited effectiveness in treating depression, anxiety, and insomnia. At a crossroads moment for many Americans, this healthcare innovation could prove immensely valuable in the years ahead.
COVID’s effect on mental health
According to a recent study released by the CDC, large disease outbreaks are associated with mental health issues, and that is again the case as we come to grips with COVID and its aftermath. The CDC reported that during the span of August 2020 through February 2021, adults dealing with symptoms of anxiety or depressive disorder increased from 36.4% to 41.5%. Even more troubling is that adults ages 18-29 years old were reporting unmet mental health care needs at an elevated rate (up from 9.2% to 11%).
These results create long-term concerns and an increased need for fresh methods such as the Fisher Wallace Stimulator. By bringing mental health to the forefront at this moment, genuine positive changes can still occur for generations of people who’ve felt as though current options were a lost cause.
Fisher Wallace’s Stimulator can reshape mental health
Already prescribed by 14,000 providers, the Stimulator is set to reshape psychotherapy and drug markets as its reputation expands among medical professionals and users alike. Freeing people from pill side effects and the pricy undertaking of pharmacy trips, this is a health-tech startup that addresses an enormous, realistic need, signaling an intriguing opportunity for investment.
Fisher Wallace is currently offering a free device, without prescription, to those who invest at least $1,500, and an updated second version is projected for production in early 2022. Thus, the laboratory is offering a chance to get in early on an innovative endeavor that is building momentum within a market clamoring for such a solution.
Fisher Wallace Laboratories has raised nearly $3 million through more than 1,500 investors. Featuring a valuation of $40 million, this mental health breakthrough is built to boost both personal health for its users and financial fortunes for those prepared to claim a piece.
You should read the Offering Circular and Risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.